Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly … Read more
Fennec Pharmaceuticals Inc (FENC) - Net Assets
Latest net assets as of September 2025: $-4.49 Million USD
Based on the latest financial reports, Fennec Pharmaceuticals Inc (FENC) has net assets worth $-4.49 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($49.21 Million) and total liabilities ($53.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-4.49 Million |
| % of Total Assets | -9.12% |
| Annual Growth Rate | N/A |
| 5-Year Change | -120.2% |
| 10-Year Change | -1171.53% |
| Growth Volatility | 4807.21 |
Fennec Pharmaceuticals Inc - Net Assets Trend (1999–2024)
This chart illustrates how Fennec Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Fennec Pharmaceuticals Inc (1999–2024)
The table below shows the annual net assets of Fennec Pharmaceuticals Inc from 1999 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-5.87 Million | +49.48% |
| 2023-12-31 | $-11.62 Million | -352.39% |
| 2022-12-31 | $-2.57 Million | -116.29% |
| 2021-12-31 | $15.77 Million | -45.74% |
| 2020-12-31 | $29.07 Million | +144.80% |
| 2019-12-31 | $11.88 Million | -44.28% |
| 2018-12-31 | $21.31 Million | -20.35% |
| 2017-12-31 | $26.76 Million | +649.50% |
| 2016-12-31 | $3.57 Million | +551.46% |
| 2015-12-31 | $548.00K | -10.60% |
| 2014-12-31 | $613.00K | +142.13% |
| 2013-12-31 | $-1.46 Million | +70.65% |
| 2012-12-31 | $-4.96 Million | -4030.83% |
| 2011-12-31 | $-120.00K | +97.56% |
| 2010-12-31 | $-4.92 Million | -1312.81% |
| 2009-12-31 | $406.00K | -86.70% |
| 2008-12-31 | $3.05 Million | -78.42% |
| 2007-12-31 | $14.15 Million | +86.53% |
| 2006-12-31 | $7.58 Million | -62.18% |
| 2005-12-31 | $20.06 Million | -39.23% |
| 2003-12-31 | $33.00 Million | +115.55% |
| 2002-12-31 | $15.31 Million | +151.79% |
| 2001-12-31 | $6.08 Million | -38.08% |
| 2000-12-31 | $9.82 Million | +20912.98% |
| 1999-12-31 | $46.73K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Fennec Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21667347500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $145.61 Million | % |
| Other Comprehensive Income | $1.24 Million | % |
| Other Components | $66.96 Million | % |
| Total Equity | $-5.87 Million | 100.00% |
Fennec Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Fennec Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Avalue Technology
TWO:3479
|
$134.61 Million |
|
Hainan Yedao Group Co Ltd
SHG:600238
|
$134.63 Million |
|
ZYF Lopsking Aluminum Co Ltd
SHE:002333
|
$134.65 Million |
|
Anora Group Oyj
HE:ANORA
|
$134.73 Million |
|
INFUSYSTEMS HLDG.DL-0001
F:1TZ
|
$134.55 Million |
|
Modiv Inc
NYSE:MDV
|
$134.52 Million |
|
Gaotu Techedu Inc
F:18WA
|
$134.39 Million |
|
Cahya Mata Sarawak Berhad
PINK:CHYMF
|
$134.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fennec Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -11,622,000 to -5,872,000, a change of 5,750,000.
- Net loss of 436,000 reduced equity.
- Share repurchases of 176,000 reduced equity.
- Other comprehensive income decreased equity by 1.
- Other factors increased equity by 6,362,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-436.00K | -7.43% |
| Share Repurchases | $176.00K | -3.0% |
| Other Comprehensive Income | $-1.00 | -0.0% |
| Other Changes | $6.36 Million | +108.34% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Fennec Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $0.09 | $7.47 | x |
| 2000-12-31 | $16.18 | $7.47 | x |
| 2001-12-31 | $6.32 | $7.47 | x |
| 2002-12-31 | $49.45 | $7.47 | x |
| 2003-12-31 | $56.83 | $7.47 | x |
| 2005-12-31 | $13.53 | $7.47 | x |
| 2006-12-31 | $5.12 | $7.47 | x |
| 2007-12-31 | $5.06 | $7.47 | x |
| 2008-12-31 | $0.99 | $7.47 | x |
| 2009-12-31 | $0.13 | $7.47 | x |
| 2010-12-31 | $-0.70 | $7.47 | x |
| 2011-12-31 | $-0.01 | $7.47 | x |
| 2012-12-31 | $-0.59 | $7.47 | x |
| 2013-12-31 | $-0.14 | $7.47 | x |
| 2014-12-31 | $0.06 | $7.47 | x |
| 2015-12-31 | $0.05 | $7.47 | x |
| 2016-12-31 | $0.28 | $7.47 | x |
| 2017-12-31 | $1.78 | $7.47 | x |
| 2018-12-31 | $1.12 | $7.47 | x |
| 2019-12-31 | $0.60 | $7.47 | x |
| 2020-12-31 | $1.23 | $7.47 | x |
| 2021-12-31 | $0.61 | $7.47 | x |
| 2022-12-31 | $-0.10 | $7.47 | x |
| 2023-12-31 | $-0.44 | $7.47 | x |
| 2024-12-31 | $-0.22 | $7.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fennec Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.92%
- • Asset Turnover: 1.06x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-244.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -3418.02% | -234898529.41% | 0.00x | 13.76x | $-1.60 Million |
| 2000 | -25.00% | -371917890.91% | 0.00x | 1.06x | $-3.44 Million |
| 2001 | -61.17% | 0.00% | 0.00x | 1.12x | $-4.33 Million |
| 2002 | -40.15% | 0.00% | 0.00x | 1.68x | $-7.68 Million |
| 2003 | -26.47% | 0.00% | 0.00x | 1.26x | $-12.04 Million |
| 2005 | -95.95% | 0.00% | 0.00x | 1.42x | $-21.25 Million |
| 2006 | -251.85% | 0.00% | 0.00x | 2.19x | $-19.86 Million |
| 2007 | -94.41% | 0.00% | 0.00x | 1.22x | $-14.77 Million |
| 2008 | -445.46% | 0.00% | 0.00x | 1.98x | $-13.91 Million |
| 2009 | -741.87% | 0.00% | 0.00x | 2.05x | $-3.05 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.33 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $4.70 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.67 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $1.99 Million |
| 2014 | -354.98% | 0.00% | 0.00x | 3.87x | $-2.24 Million |
| 2015 | -120.26% | 0.00% | 0.00x | 1.86x | $-713.80K |
| 2016 | -78.12% | 0.00% | 0.00x | 1.11x | $-3.15 Million |
| 2017 | -26.33% | 0.00% | 0.00x | 1.06x | $-9.72 Million |
| 2018 | -46.39% | 0.00% | 0.00x | 1.08x | $-12.02 Million |
| 2019 | -104.93% | 0.00% | 0.00x | 1.19x | $-13.65 Million |
| 2020 | -62.29% | -10652.35% | 0.01x | 1.08x | $-21.02 Million |
| 2021 | -109.01% | -10113.75% | 0.01x | 1.42x | $-18.77 Million |
| 2022 | 0.00% | -1544.89% | 0.05x | 0.00x | $-22.52 Million |
| 2023 | 0.00% | -75.50% | 0.79x | 0.00x | $-14.88 Million |
| 2024 | 0.00% | -0.92% | 1.06x | 0.00x | $151.20K |
Industry Comparison
This section compares Fennec Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fennec Pharmaceuticals Inc (FENC) | $-4.49 Million | -3418.02% | N/A | $134.57 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |